This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vyndaqel

Pfizer Inc.

Drug Names(s): Fx-1006A, tafamidis meglumine

Description: Fx-1006A stabilizes the protein transthyretin (TTR), preventing dissociation of the native TTR tetramer into monomers, resulting in the inhibition of TTR amyloid fibril formation. The dissociation of TTR is implicated in TTR amyloidosis.

Deal Structure: Tafamidis was originally developed by FoldRx.

In September 2010, Pfizer entered into an agreement to acquire FoldRx. Pfizer will make an upfront payment and contingent payments if certain milestones are achieved. Specific financial terms were not disclosed. The acquisition was completed in October 2010.


Vyndaqel News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug